Standout Papers

Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised... 2019 2026 2021 2023 256
  1. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial (2019)
    Bernard Zinman, Vaishali Bhosekar et al. The Lancet Diabetes & Endocrinology

Immediate Impact

4 from Science/Nature 103 standout
Sub-graph 1 of 21

Citing Papers

Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
2025 Standout
Engineered commensals for targeted nose-to-brain drug delivery
2025 Standout
2 intermediate papers

Works of James Thrasher being referenced

Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial
2019 Standout

Author Peers

Author Last Decade Papers Cites
James Thrasher 450 177 292 20 598
Whitney Sealls 412 166 317 13 629
M. Nauck 428 271 181 25 715
Marie‐Louise Hartoft‐Nielsen 423 96 225 17 609
Paolo Pinna Parpaglia 308 180 169 26 720
Kimberly M. Hoagland 413 101 226 16 728
Richard Urquhart 373 117 473 15 703
Amanda Garza 264 113 240 28 563
Xiaosu Ma 390 205 161 21 567
Andrea Delbarba 262 120 167 23 604
Hisashi Yokomizo 271 172 257 26 714

All Works

Loading papers...

Rankless by CCL
2026